Skip to content

Propolis Extract, Nanovitamin C and Nanovitamin E in Peri-implant Mucositis

Effect of Propolis Extract, Nanovitamin C and Nanovitamin E in Clinical and Microbiological Parameters of Peri-implant Mucositis: A Double-blind, Randomized, Clinical Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04215432
Enrollment
46
Registered
2020-01-02
Start date
2018-05-01
Completion date
2019-12-21
Last updated
2020-01-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peri-implant Mucositis

Keywords

dental implants, peri-implant mucosits, toothpaste, propolis, nanovitamin

Brief summary

The objective of this study was to perform the first clinical trial to evaluate the effectiveness of propolis extract, nanovitamin C and nanovitamin E gel as adjuvant to mechanical debridement in clinical and microbiological parameters of implants with peri-implant mucositis

Interventions

DEVICEGel containing propolis extract, nanovitamin C and nanovitamin E

The patient had to use the gel as a toothpaste and apply it with an interdental brush in mesial and distal aspects of the implant with peri-implant mucositis. during 1 month.

DEVICEPlacebo

The patient had to use the gel as a toothpaste and apply it with an interdental brush in mesial and distal aspects of the implant with peri-implant mucositis.

Sponsors

Bio Nature Essences S.L
CollaboratorUNKNOWN
Universidad Complutense de Madrid
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Caregiver)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* cooperative adult patients, * with one or more implants with peri-implant mucositis, and * presenting at least 18 months of functional loading.

Exclusion criteria

* refuse to participate in the study, * patients who had implants with peri-implantitis (BOP and/or suppuration together with progressive radiographic marginal bone loss), * patients with uncontrolled periodontitis (presence of nine or more sites with PD ≥ 5 mm and with full-mouth bleeding score (FMBS) \> 25%), * systemic diseases or conditions that could alter the results of the study (diabetes mellitus, immunosuppression, infectious diseases, rheumatoid disease, history of bisphosphonate treatment, radiotherapy, chemotherapy, etc.), * patients who had taken local and/or systemic antibiotics less than 2 months ago, * pregnant or breastfeeding women, and * patients with history of allergies to the test and/or placebo components administered.

Design outcomes

Primary

MeasureTime frameDescription
Changes in bleeding on probingbaseline and 1-month follow-upIt was present when it appeared bleeding at the gingival margin after recording probing depths at six sites in each implant. Modified bleeding index was also collected.

Secondary

MeasureTime frameDescription
Changes in probing depthbaseline and 1-month follow-upIt was recorded at six sites of each implant with PM, using a probe with a force of 0.2N (PCV12; HuFriedy, Chicago, IL, EEUU).
Changes in plaque indexbaseline and 1-month follow-upIt was recorded after using a disclosing dye, as the presence of dental plaque at the gingival margin at six sites in each implant.
Changes in microbilogical samplebaseline and 1-month follow-upMicrobiological samples were obtained at the deepest peri-implant pocket. Firstly, the area was isolated using cotton rolls and dried with a gentle air blow. Then, three sterile paper tips (#30, Maillefer, Ballaigues, Switzerland) were left for 10 seconds at the point with the greatest peri-implant pocket depth. Finally, the papers were introduced in a vial containing 1.5 ml of reduced transport fluid. The vials were sent to the microbiology laboratory of the School of Dentistry, at Complutense University of Madrid for an anaerobic culture within 24 hours. Total counts and counts of target periodontal pathongens \[Aggregatibacter actinomycetemcomitans, Porphyromonas gingivalis, Prevotella intermedia, Tannerella forsythia, Parvimonas micra, Fusobacterium nucleatum, Campylobacter rectus, Eikenella corrodens, Capnocytophaga sp., Actinomyces odontolyticus\] were determined after 7-14 days of anaerobic incubation. Then, those results were converted in colony-forming units per ml.

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026